All In Biotech

Drug Trial Radar · NCT07537881

A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors

A Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RC288 for Injection in the Treatment of Locally Advanced Unresectable or Metastatic Malignant Solid Tumor.

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

326

Planned (sponsor's estimate)

Start

Apr 27, 2026

Primary completion

Dec 30, 2029

Study completion Jun 30, 2030

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate the safety and tolerability of RC288; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC288; and determine the recommended phase 2 dose (RP2D), and assess the efficacy of RC288 at the RP2D dose;

Conditions

  • Solid Tumors

Interventions

  • RC288 For InjectionDrug

    Intravenous (IV) administration of RC288. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study.

  • RC288 For InjectionDrug

    Intravenous (IV) administration of RC288. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity (DLT)Time frame: 24 months
  2. Incidence and severity of adverse events/serious adverse events (graded according to NCI CTCAE v6.0)Time frame: 24 months
  3. Determine RP2D of RC288Time frame: 24 months
  4. MTD and/or MADTime frame: 24 months
  5. Prostate Cancer Cohort: Investigator assessed ORR according to RECIST v1.1 criteria and PCWG3 criteriaTime frame: 24 months
  6. Non-Prostate Cancer Cohort: Investigator assessed ORR according to RECIST v1.1 criteriaTime frame: 24 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Hunan Cancer Hospital

    Hunan, Changsha, China · Not yet recruiting

  • Sichuan Cancer Hospital & Institute

    Sichuan, Chengdu, China · Not yet recruiting

  • Fujian Cancer Hospital

    Fujian, Fuzhou, China · Not yet recruiting

  • Fujian Medical University Union Hospital

    Fujian, Fuzhou, China · Not yet recruiting

  • Sun Yat sen University Cancer Center

    Guangdong, Guangzhou, China · Not yet recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guizhou, Guiyang, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Heilongjiang, Haerbin, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Cancer Hospital of Shandong First Medical University Cancer Hospital

    Shandong, Jinan, China · Not yet recruiting

  • Shanxi Cancer Hospital

    Shandong, Jinan, China · Recruiting

  • Shanxi Cancer Hospital

    Shanxi, Shanxi, China · Recruiting

  • Taizhou Hospital of Zhejiang Province

    Zhejiang, Taizhou, China · Not yet recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Zhejiang, Wenzhou, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.